Biomedical Engineering Reference
In-Depth Information
of. important. viral. diseases.. We. have. developed. virus-speciic,. yet. broadly. neutralizing,.
nanoviricides,.using.ligands.speciic.to.certain.viruses,.such.as.HIV,.inluenza,.and.EKC,.
among.others,.as.well.as.broad-spectrum.nanoviricides.that.are.highly.effective.against.
many. distinctly. different. types. of. viruses,. using. ligands. that. mimic. common. virus. cell.
binding.features.
References
. 1.. Von.Herrath,.M.G.,.D.P..Berger,.D..Homann,.T..Tishon,.A..Sette,.and.M.B..Oldstone..Vaccination.
to.treat.persistent.viral.infection..
Virology
.268:411,.2000.
. 2.. Lindenburg,.C.E.,.I..Stolte,.M.W..Langendam,.F..Miedema,.I.G..Williams,.R..Colebunders,.J.N..
Weber,.M..Fisher,.and.R.A..Coutinho..Long-term.follow-up:.no.effect.of.therapeutic.vaccina-
tion.with.HIV-1.p17/p24:Ty.virus-like.particles.on.HIV-1.disease.progression..
Vaccine
.20:2343,.
2002.
. 3.. Dikici,.B.,.A.G..Kalayci,.F..Ozgenc,.M..Bosnak,.M..Davutoglu,.A..Ece,.T..Ozkan,.T..Ozeke,.R.V..
Yagci,.and.K..Haspolat..Therapeutic.vaccination.in.the.immunotolerant.phase.of.children.with.
chronic.hepatitis.B.infection..
Pediatric Infectious Diseases Journal
.22:345,.2003.
. 4.. Nevens,.F.,.T..Roskams,.H..Van.Vlierberghe,.Y..Horsmans,.D..Sprengers,.A..Elewaut,.V..Desmet,.
G..Leroux-Roels,.E..Quinaux,.E..Depla,.et.al..A.pilot.study.of.therapeutic.vaccination.with.enve-
lope.protein.E1.in.35.patients.with.chronic.hepatitis.C..
Hepatology
.38:1289,.2003.
. 5.. Rappuoli,.R..Bridging.the.knowledge.gaps.in.vaccine.design..
Nature
.
Biotechnology
.25:1361,.2007.
. 6.. Boni,.M.F..Vaccination.and.antigenic.drift.in.inluenza..
Vaccine
.26.(Suppl.3):C8,.2008.
. 7.. Treanor,.J..Inluenza.vaccine—outmaneuvering.antigenic.shift.and.drift..
New England Journal of
Medicine
.350:218,.2004.
. 8.. Fox,.J.L..Antivirals.become.a.broader.enterprise..
Nature
.
Biotechnology
.25:1395,.2007.
. 9.. Pauwels,.R..Aspects.of.successful.drug.discovery.and.development..
Antiviral Research
.71:77,.2006.
. 10.. De.Clerq,.E..Three.decades.of.antiviral.drugs..
Nature Reviews Drug Discovery
.6:941,.2007.
. 11.. Harper,. S.A.,. J.S.. Bradley,. J.A.. Englund,. T.M.. File,. S.. Gravenstein,. F.G.. Hayden,.A.J.. McGeer,.
K.M.. Neuzil,.A.T.. Pavia,. M.L.. Tapper,. T.M.. Uyeki,. and. R.K.. Zimmerman.. Seasonal. inluenza.
in. adults. and. children—diagnosis,. treatment,. chemoprophylaxis,. and. institutional. outbreak.
management:.clinical.practice.guidelines.of.the.Infectious.Diseases.Society.of.America..
Clinical
Infectious Diseases
.48:1003,.2009.
. 12.. WHO. Guidelines. on. the. use. of. vaccines. and. antivirals. during. inluenza. pandemics.. WHO/
CDS/CSR/RMD/2004.8.
. 13.. Broder,.S..The.development.of.antiretroviral.therapy.and.its.impact.on.the.HIV-1/AIDS.pan-
demic..
Antiviral Research
.85:1,.2010.
. 14.. Hayden,. F.G.. Antivirals. for. inluenza:. historical. perspective. and. lessons. learned..
Antiviral
Research
.71:372,.2006.
. 15.. De.Clerq,.E..The.design.of.drugs.for.HIV.and.HCV..
Nature Reviews Drug Discovery
6:1001,.
2007.
. 16.. Kwon,.G.S..Polymeric.micelles.for.delivery.of.poorly.water-soluble.compounds..
Critical Reviews
in Therapeutic Drug Carrier Systems
.20:357,.2003.
. 17.. Aliabadi,. H.M.,. and. A.. Lavasanifar.. Polymeric. micelles. for. drug. delivery..
Expert Opinion in
Drug Delivery
.3:139,.2006.
. 18.. Uchegbu,.I.F..Pharmaceutical.nanotechnology:.polymeric.vesicles.for.drug.and.gene.delivery..
Expert Opinion in Drug Delivery
.3:629,.2006.
. 19.. Johansson,.S.M.C.,.N..Arnberg,.M..Elofsson,.G..Wadell,.and.J..Kihlberg..Multivalent.HSA.con-
jugates. of. 3'-sialyllactose. are. potent. inhibitors. of. adenoviral. cell. attachment. and. infection..
Chem Bio Chem
.6:358,.2005.
